Inovio Pharmaceuticals, Inc.(INO)

$1.29—Stale · unknown old

Chart

Inovio Pharmaceuticals, Inc.(INO)

NASDAQ • Last print unknown ago

$1.29—Stale · unknown old

Chart Studio

INO(INO)

INO

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.20

Nov 10, 2026 · Reports after close

Revenue Estimate

$2M

FY2029E EPS$0.27

FY2030E EPS$0.66

Analyst Sentiment

Wall St. Consensus

Buy

16 analysts·Moderate coverage

Score

10 Buy (63%)4 Hold (25%)2 Sell (12%)

Rating Breakdown

Strong Buy

00%

Buy

1063%

Hold

425%

Sell

213%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$2.50

+93.8%

Consensus

$2.75

+113.2%

Bull

$3.00

+132.6%

12-Month Target Range16 analysts

$2.50$2.75$3.00

Current $1.29Consensus

Current Price

$1.29

Upside to Consensus

$1.46

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+7490.00%

EPS—

FY2028

Rev+56.32%

EPS—

FY2029

Rev+98.86%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$666,667	$51M	$79M	$157M	$222M
Low	$416,331	$37M	$49M	$98M	$139M
High	$873,877	$64M	$104M	$206M	$292M
EBITDA Avg	$-33M	$-11M	$13M	$50M	$95M
Low	$-33M	$-22M	$11M	$42M	$75M
High	$-32M	$-676,851	$15M	$56M	$110M
EBIT Avg	$-35M	$-20M	$-4M	$16M	$40M
Low	$-36M	$-30M	$-6M	$9M	$21M
High	$-35M	$-9M	$-2M	$23M	$55M
Net Income Avg	$-36M	$-20M	$-4M	$13M	$31M
Low	$-36M	$-30M	$-7M	$6M	$16M
High	$-35M	$-10M	$-2M	$18M	$43M
EPS Avg	$-0.76	$-0.43	$-0.10	$0.27	$0.66
Low	$-0.77	$-0.65	$-0.14	$0.14	$0.34
High	$-0.75	$-0.20	$-0.05	$0.38	$0.93
Analysts (Rev / EPS)	2 / 2	2 / 2	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$2M	$666,667	$7M	$14M	$21M	$28M
Low	$2M	$666,667	$7M	$14M	$21M	$28M
High	$2M	$666,667	$7M	$14M	$21M	$28M
EBITDA Avg	$-16M	$-15M	$-14M	$-10M	$-6M	$-2M
Low	$-16M	$-15M	$-14M	$-10M	$-6M	$-2M
High	$-15M	$-15M	$-14M	$-10M	$-6M	$-2M
EBIT Avg	$-16M	$-15M	$-14M	$-11M	$-8M	$-4M
Low	$-16M	$-15M	$-14M	$-11M	$-8M	$-4M
High	$-15M	$-15M	$-14M	$-11M	$-8M	$-4M
Net Income Avg	$-16M	$-15M	$-14M	$-11M	$-8M	$-4M
Low	$-16M	$-15M	$-14M	$-11M	$-8M	$-4M
High	$-15M	$-15M	$-14M	$-11M	$-8M	$-4M
EPS Avg	$-0.20	$-0.18	$-0.17	$-0.13	$-0.10	$-0.06
Low	$-0.20	$-0.18	$-0.17	$-0.13	$-0.10	$-0.06
High	$-0.19	$-0.18	$-0.17	$-0.13	$-0.10	$-0.06
Analysts (Rev / EPS)	2 / 2	2 / 2	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 13, 2026Jefferies

Inovio upgraded to Buy from Hold at Jefferies

Target:$3.00

+233.4%from $0.90

Jun 1, 2026H.C. Wainwright

Inovio price target lowered to $2.50 from $3 at H.C. Wainwright

Target:$2.50

+90.8%from $1.31

Nov 14, 2025Piper Sandler

'Inovio Pharmaceuticals (INO) Raises $28.75M to Fund Operations'; PT Raised at Piper Sandler

Target:$6.00

+201.5%from $1.99

Aug 9, 2024RBC Capital

Inovio Pharmaceuticals (INO) PT Lowered to $8 at RBC Capital

Target:$8.00

-8.2%from $8.71

May 14, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Inovio Pharmaceuticals (INO)

Target:$40.00

+249.5%from $11.45

May 13, 2024Stephens

Inovio initiated with an Overweight at Stephens

Target:$20.00

+76.1%from $11.36

Jan 25, 2024Oppenheimer

Oppenheimer Upgrades Inovio Pharmaceuticals (INO) to Outperform

Target:$4.00

-41.1%from $6.79

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance